Shots:

• Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally- it is eligible to receive upto $660M in future clinical- regulatory and commercial milestone payments along with royalties based upon the w/w sales after receiving a $25M milestone
• Jounce led the development of JTX-1811 through IND clearance- and thereafter Gilead has exclusive rights to develop and commercialize the program
• JTX-1811 is a mAb- targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells

  | Ref: Globe Newswire | Image: Gilead